Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Reviving lixivaptan

How Palladio plans to repurpose lixivaptan for ADPKD

Mark Zipkin, Staff Writer
March 9, 2018 3:42 AM UTC

Single-asset play Palladio Biosciences Inc. is repurposing lixivaptan as a safer alternative to Jinarc tolvaptan, a competing vasopressin 2 (V2) receptor antagonist associated with hepatotoxicity in patients with autosomal dominant polycystic kidney disease.

ADPKD is characterized by cyst formation and kidney enlargement, which can eventually lead to kidney failure. According to the company, about half of ADPKD patients require dialysis or kidney transplantation by age 60...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Chiesi Farmaceutici S.p.A.

Otsuka Pharmaceutical Co. Ltd.

Palladio Biosciences Inc.

Sanofi

U.S. Food and Drug Administration (FDA)